Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 10872.145 | 1.0365 | 1.0445 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10872.145 | 1.0051 | 1.0063 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10872.145 | 0.9500 | 0.9381 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 10872.145 | 0.9784 | 0.9734 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 10872.145 | 0.9763 | 0.9708 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 10872.145 | 1.0385 | 1.0468 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 10872.145 | 1.0348 | 1.0423 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 12523.17 | 0.9867 | 0.9705 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 12523.17 | 0.9767 | 0.9483 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 12523.17 | 0.9660 | 0.9246 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 12523.17 | 0.9950 | 0.9888 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 12523.17 | 0.9762 | 0.9472 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 12523.17 | 1.0381 | 1.0850 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 12523.17 | 0.9605 | 0.9123 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 12523.17 | 0.9385 | 0.8636 | 0.8990 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 12523.17 | 1.0464 | 1.1034 | 0.8990 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 12239.145 | 0.9804 | 0.9815 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 12239.145 | 0.9193 | 0.9227 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 12239.145 | 0.9584 | 0.9605 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 12239.145 | 1.0528 | 1.0488 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 12239.145 | 0.9697 | 0.9714 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 12239.145 | 0.9760 | 0.9774 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 12239.145 | 0.9667 | 0.9686 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 12239.145 | 1.0209 | 1.0195 | 2.1348 | |
| HCC1806 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 12239.145 | 0.9575 | 0.9597 | 2.1348 |